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In this study, we compared a puriﬁed aqueous extract and the corresponding nonpuriﬁed aqueous preparation under the same
build-up protocol in bee venom allergic patients with a normal baseline mast cell tryptase concentration. Eighty patients with
a history of a systemic reaction were enrolled for immunotherapy using a 5-day rush protocol. Patients treated with the puriﬁed
extractandthosetreatedwiththenonpuriﬁedaqueousextractwhodevelopedasystemicreactionunderwentmaintenancetherapy
with the puriﬁed aluminium hydroxide adsorbed preparations. Patients treated with the nonpuriﬁed aqueous extract who did not
experience a systemic reaction during the rush phase underwent the maintenance phase with that extract. Systemic reactions
during the build-up phase occurred signiﬁcantly more often in patients treated with nonpuriﬁed aqueous extract than in those
treated with the corresponding puriﬁed aqueous preparations. During the one-year maintenance phase, no systemic reactions
occurred in either of the groups. Neither age nor baseline mast cell tryptase concentration presented a signiﬁcant correlation with
the occurrence of a systemic reaction during the treatment, while the type of extract did. In conclusion, nonpuriﬁed aqueous
extracts induced more frequent systemic reactions than the puriﬁed aqueous preparations, during the same rush protocol. The
eﬃcacy seemed to be comparable.
1.Introduction
Subcutaneous VIT with a standard dose of 100μg is highly
eﬀective treatment [1, 2]. The indications for VIT are a
history of an SR, positive venom skin or serum-speciﬁc
IgE antibodies [1, 3], the knowledge of the natural history
and risk factors for severe outcome [4], and impaired
quality of life [5]. VIT can however have side eﬀects, the
most serious being anaphylaxis [1, 6]. HB venom and the
build-up phase are well-known risk factors for side eﬀects
during VIT. Although there are no deﬁnite conclusions
regarding the role of the dose increase schedule [6, 7], in
a recent European multicentre study of 680 VIT patients,
the rapid dose increase (ultrarush > rush > conventional
phase) appears to be a risk factor for side eﬀects during
the build-up phase [8]. Moreover, mast cell diseases and
also an elevated bSTC represent other risk factors [8, 9]. In
Europe, VIT may be performed using PA and NPA venom
extracts and PAHA preparations (depot preparations). The
latter of the three is used in the conventional build-up and
maintenancephases,whiletheaqueouspreparationsareused
inultra-rush,rush,clustered,andmaintenancephases.Many
European specialists switch from the aqueous extracts to
PAHA preparations after updosing, whether or not they
cause side eﬀects [10]. The eﬃcacy of the PA and PAHA
extracts is supported by studies using both sting challenge
and in-ﬁeld stings and is comparable to that of nonpuriﬁed
preparations [11]. In comparative trials, both PA and PAHA
extracts appear to be better tolerated than NPA extracts,
especially in the prevention of severe large local reactions
(LLRs) [11, 12].2 Journal of Allergy
As PA extracts and the corresponding NPA extracts in
HBV-allergic patients have not been compared so far, this
study aims to prospectively compare treatment safety in
terms of SRs by administering PA and the corresponding
NPA bee-venom extracts during the same rush phase in
patients with a normal bSTC and evaluate the safety of depot
versus NPA extracts during a one-year maintenance phase.
2.MaterialandMethods
2.1. Patients. Consecutive HBV-allergic patients with a his-
tory of a SR ≥ Mueller grade II [13] were enrolled for VIT
with a PA or the corresponding NPA extract. A diagnosis
of HBV allergy was made if the patient had a history of
an SR to a honeybee sting, was positive to skin testing,
and/or had serum speciﬁc IgE to Apis mellifera venom [3].
Pregnancy and beta-blocker treatment were considered as
standard exclusion criteria [3], as well as mastcell diseases
and also a bSTC ≥ 11.5μg/L (Immunoﬂuorimetric CAP
assay, Unicap 100; Phadia, Uppsala, Sweden).
TheLocalEthicsCommitteeapprovedtheStudyProtocol
and patients gave their written informed consent.
2.2. Allergen Extracts for VIT. The following extracts were
used for treatment: (1) the traditional NPA HBV prepara-
tions(PharmalgenALK-Abell` oaqueousextracts,HØrsholm,
Denmark), reconstituted in albumin-containing saline dilu-
ent; (2) a PA HBV preparation (Aquagen SQ, ALK-Abell` o);
(3) a puriﬁed aluminium-adsorbed HBV depot prepara-
tion (Alutard SQ, ALK-Abell` o). All preparations contain
100μg/mL of allergens. PA venom extracts are products with
no low-molecular components present in the native venom
extract (cutoﬀ: 1000D). Puriﬁcation is mainly obtained
through a Sephadex-gel ﬁltration process, which allows sep-
aration of the protein fractions by means of their molecular
weight. PA venom extracts do not contain vasoactive amines
like dopamine, histamine, and serotonin. In addition, a gel-
ﬁltration procedure reduces the presence of small peptides
like apamin, kinins, and mast cell degranulating peptides
in the ﬁnal product. In the PAHA extract, the raw venom
underwent the same puriﬁcation procedure with recovery
of the allergen-containing fraction only and subsequently
adsorbed onto aluminium hydroxide.
2.3. Treatment Regimens. The patients underwent a 5-day
rush VIT regimen (Table 1) with the aqueous preparations
and were split into groups A (40 patients) and B (40
patients), which were administered NPA (Pharmalgen ALK-
Abell` o )a n dP Ae x t r a c t s( A q u a g e nS Q ,A L K - A b e l l` o), respec-
tively. Patients experiencing SRs during the build-up phase
from both groups were switched from the aqueous to the
PAHA extract and received weekly interval injections of up
to 100μg of venom. During the maintenance phase, group A
patientswhodevelopednorush-phaseSRswentontoreceive
maintenance therapy with the non-puriﬁed aqueous extract
whilegroupBpatientswhotoleratedthebuild-upphasewere
also treated with the PAHA preparation. Maintenance VIT
Table 1: Protocol of VIT build-up rush phase.
Day Dose mL administered μg administered Conc μg/mL
1
1 0.10 0,01 0,1
2 0.10 0,1 1
30 . 1 0 1 1 0
40 . 2 0 2 1 0
2
50 . 3 0 3 1 0
6 0.35 3,5 10
7 0.35 3,5 10
3
8 0.10 10 100
9 0.15 15 100
10 0.15 15 100
4
11 0.20 20 100
12 0.25 25 100
13 0.25 25 100
5
14 0.30 30 100
15 0.35 35 100
16 0.35 35 100
was performed in both groups at 4 weekly intervals for one
year. The patients were not administered premedication.
2.4. Adverse Reactions. Only those patients with a history of
anaphylaxis undergoing rush VIT were hospitalised in our
clinic.Theotherpatientswerekeptonanoutpatientregimen
on the day of treatment. Injections were administered in
our clinic by the same allergist. SRs to VIT injections were
Mueller classiﬁed [13].
Development of an SR during the rush-phase neces-
sitated suspending treatment until the patient made a
complete recovery, after which a depot extract was used. In
the event of a large local or a mild SR, the VIT dosage was
maintained. Weekly interval injections up to the standard
maintenance dosage were then administered.
Patients were instructed to immediately report any sus-
pected delayed VIT-related reactions experienced at home.
2.5. Eﬃcacy. The use of hospital sting challenges remains
an ethical issue in Italy and is generally avoided for testing
VIT eﬃcacy. This being the case, patients were instructed
to report details of any reaction to a ﬁeld sting and any
pharmacological treatment. To assess treatment eﬃcacy in
non beekeepers, only those stings typically attributable to
bees, recognisable by the embedded stinger at the sting site,
were considered.
2.6. Statistics and Sample Size Calculation. Statistical analysis
was carried out using SPSS statistical software (vers. 13)
(SPSS Chicago, IL, USA). Diﬀerences between the two
groups in outcome variables (i.e., occurrence of SRs) were
assessed using Fisher’s exact test (whenever an expected cell
value was <5) and the χ-square test. Relative risks with
95% CI were also calculated. The number needed to harm
(NNH) was calculated according to McQuay and Moore
[14]. A multiple-logistic regression analysis was performedJournal of Allergy 3
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Figure 1: Study ﬂow for the build-up phase of VIT.
Table 2: Demographic and clinical data of patients included in the
study.
Group A
(Nonpuriﬁed)
N = 40
Group B
(puriﬁed)
N = 40
P values
Sex (male/female) 34/6 30/10 0.8
Age, years, mean (SD) 42 (17) 42 (16) 0.8
Mueller classiﬁcation
(Reaction to HB sting)
Grade I 0 0
0.7 Grade II 7 9
Grade III 15 13
Grade IV 18 18
to identify clinical and demographic variables (age, gender,
reaction severity, baseline STC, type of VIT, puriﬁed versus
non-puriﬁed) associated with the occurrence of SRs during
VIT. The unpaired t-test and Mann-Whitney test, when
appropriate, were used to compare quantitative variables. A
two-sided P value < 0.05 was considered signiﬁcant for all
analyses.
The power calculation assumed a diﬀerence between PA
and NPA treated subjects in the incidence of SRs of at least
65% less (relative risk reduction). This assumption provided
80% power at an alpha level of 0.05 for a sample size of at
least 40 evaluable patients per group. Sample size calculation
was performed using GPower Statistical Software ver 3.03
(Germany).
3. Results
3.1. Patients. Ninety-seven consecutive patients with a his-
tory of an SR to HB stings were evaluated for the study,
of whom 17 (17.5%) were excluded on the grounds of a
bSTC ≥ 11.5μg/L (Figure 1), leaving 80 to be allocated to
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Figure 2: Baseline serum tryptase level (μg/L) in patients treated
with puriﬁed aqueous HB venom extract (Group A) and in patients
treated with non-puriﬁed aqueous preparation (Group B).
twotreatmentgroups:40ingroupAand40ingroupB.Prior
to VIT, 16 patients (20%) had experienced a grade II SR, 28
patients (35%) a grade III SR, and 36 patients (45%) a grade
IV SR. The two groups of patients (cases and controls) were
comparable with respect to age, sex, bSTC and SR severity
(Table 2 and Figure 2).
3.2. Adverse Reactions
3.2.1. Dose Increase Phase. The cumulative doses during
the tolerated 5-day rush-phase was 223.11μgo fH B V .
Eleven (27.5%) (95%CI: from 13 to 41%) group A patients
developed an immediate SR: 6 were grade I reactions and
5g r a d eI I( Table 3). Treatment was suspended in these
patients until they fully recovered, and in almost without
exceptionVITwasresumedwiththeequivalentdosageofthe
PAHA extract. A maintenance dose of 100μg was reached by
weekly interval injections, with no side eﬀects. Thirty-nine4 Journal of Allergy
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Figure 3: Study ﬂow for the build-up and maintenance phases of VIT.
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Figure 4: Baseline serum tryptase level in patients who developed
a systemic reaction (SR) during the build-up phase of VIT in
comparison with those who did not.
group B patients tolerated the rush-phase and then switched
to the PAHA extract for the HBV 100μg maintenance
therapy with no side eﬀects (Figure 3). One (2.5%) (95%
Table 3: Systemic reaction during the build-up phase of VIT.
Build-up 5-day rush phase
Group no. of patient VIT day SR∗
(A) Aqueous non-puriﬁed
22 I I
12 I
33 I I
33 I
14 I
15 I
(B) Aqueous puriﬁed 1 3 I
∗According to Mueller classiﬁcation [13].
CI: from 2 to 7%) group B patients developed a grade I
SR (Table 3) and switched from the aqueous puriﬁed extract
to the PAHA extract (Figure 3), with no SR, successfully
reaching the maintenance dose of 100μg, with the result that
patients treated with the NPA extract during the rush phase
experienced signiﬁcant more frequent SRs than those who
underwent VIT with the PA extract (P = 0.0017 Fisher’s
exact test). The absolute risk reduction was 25%, and theJournal of Allergy 5
relative risk (puriﬁed versus nonpuriﬁed extracts) was 91%
(95% CI from 100 to 53) with a NNH of 4.2. In the rush
induction phase, the incidence of SRs per total number of
injections (i.e 634) was 0.1%/doses in the puriﬁed-extract-
treated patients (group A) compared to 1.9%/doses in the
nonpuriﬁed-extract-treated group of patients (total number
of injections 555) (P = 0.0017 Chi-squared test). No patient
in group A or B experienced late SRs.
3.2.2. Maintenance Phase. Maintenance dose was 100μgi n
all patients. Twenty-nine group A patients underwent one-
year maintenance treatment with the NPA extract, while 51
(11 group A and 40 group B patients) were given the PAHA
extract (Figure 3). No SRs occurred.
3.3. Tryptase Dosage. The mean (SD) value of bSTC was 5
(±2.3) μg/L (median 4.5) and 5.3 (±2) μg/L (median 4.7) in
groupAandBpatients,respectively(P =n.s.)(Figure 2).The
mean value of bSTC was 5,6μg/L (median 5.5) in patients
who developed SRs and 5.3μg/L (median 5.4) in those who
did not (P = n.s.) (Figure 4). Multiple logistic regression
analysis did not reveal a signiﬁcant correlation between the
occurrence of an SR during VIT with age, gender, reaction
severity, or basal STCs, while, in contrast, the type of extract
(NPA) correlated signiﬁcantly (P = 0.0001).
3.4. Eﬃcacy. No patient was re-stung during the build-up
phase. Thirteen out of the 29 (44.8%) NPA extract treated
patients were re-stung during the one year maintenance
phase without developing a reaction.
Fifteen out of the 51 patients (13.6%) treated with the
PAHA extract during the maintenance phase were re-stung
without side eﬀects, of whom one developed a mild SR
during VIT.
4. Discussion
While probably being the most eﬀective form of allergen
immunotherapy currently available to physicians [1, 2, 10],
subcutaneousVITisatthesametimeabletoimprovehealth-
related quality of life [5]. However, the treatment can cause
side eﬀects ranging from an LLR to a severe SR [1]. A
recent paper comparing puriﬁed preparations with non-
puriﬁed extracts reviewed the literature on the respective
safety and eﬀectiveness of the two [12]. The authors found
thatincomparativetrialspuriﬁedextractsappeartobebetter
tolerated than non-puriﬁed extracts, while PAHA extracts
seem to be safer than the corresponding PA preparation,
especially in the prevention of severe LLRs. Also, they
concluded that further prospective-controlled studies are
needed in order to evaluate the ability of puriﬁed extracts
to reduce the frequency of SRs over the corresponding non-
puriﬁed preparation [12].
Thisistheﬁrststudycomparingthesafetyofpuriﬁedand
the corresponding non-puriﬁed aqueous venom prepara-
tions in terms of SRs in HBV-allergic patients with a normal
bSTC under the same build-up protocol. We studied HV-
venom-allergic patients as their risk of developing an SR
during VIT is greater than that of vespid-allergic patients
[1]. The scope of our paper is conﬁned to the study of VIT-
induced SRs. LLRs, though frequent and bothersome, do not
usually necessitate a dose reduction and do not prevent from
reaching the full maintenance dose. They are also no risk
factor for SRs to later injections.
Patients with a bSTC ≥ 11.5μg/L were excluded as this
factor itself is a potential risk for side eﬀects during VIT.
Indeed, a recent paper reports that a rise in the bSTC from
4.21μg/L to 20μg/L only in vespid allergic patients is ac-
companied by a simultaneous increase in requirement for
emergency intervention during the build-up phase by a
factor of approximately 3.75 [8].
In this study, we compared the same build-up protocol
in two homogeneous groups of patients who were treated
with two diﬀerent extracts from the same company. We
have demonstrated that patients treated with the non-
puriﬁed HBV experienced signiﬁcantly more SRs than those
treated with the puriﬁed HBV preparation, due to a higher
occurrence of SRs during the build-up phase. In fact, during
the same 5-day rush phase, 27.5% of the NPA-extracts-
treated patients developed an SR compared with 2.5% of
the PA-extract-treated subjects (P = 0.0017; NNH = 4.2).
Reactions were nonsevere with six patients developing a
g r a d eIa n dﬁ v eag r a d eI Ir e a c t i o n .T h el o w e rf r e q u e n c yo f
SRs following injections of the PA preparations compared
with the NPA extracts, as demonstrated by our study, may
be due to the former’s puriﬁcation of low-molecular-weight
irritants, with recovery of the allergen-containing fraction
only. This ﬁnding cannot be attributed to the cumulative
dose applied over a given span of time as the two groups of
patients underwent the same 5-day rush protocol.
Patients who had SRs during the build-up phase were
switched to the PAHA extract from the NPA solution, as
were those treated with the PA extract whether they had
experienced an SR or not. During the one-year maintenance
phase, no SRs occurred in either group. Though there was no
control group, our data indirectly conﬁrm the safer proﬁle of
thePAHAextracts.Infact,allthosepatientswhoexperienced
PA- or NPA-induced SRs during the rush phase could
have beneﬁted from being switched to the same dosage of
a PAHA preparation and have subsequently achieved the
100μg maintenance dose with weekly interval injections.
To date, the only study which compares PA and PAHA
extracts with the corresponding NPA preparations dates
back to 1986 and was done in yellow-jacket-venom- (YJV-)
allergic patients. The authors demonstrated that PA-induced
SRs were milder than those caused by NPA preparations, but
more frequent with the PAHA extracts [15]. In HBV-allergic
patients,afewstudiescomparethePAHAextractwiththePA
extract under diﬀerent protocols [16–18], but none with the
corresponding NPA extract. In HBV-allergic patients, Rueﬀ
demonstrated that treatment with the PA extract caused
signiﬁcantly more frequent LLRs than the depot extract
during the 5-day rush and maintenance phases. On the other
hand, though not signiﬁcant, aqueous preparations induced
SRs more frequently during the updosing phase [16].
Another study of HBV-allergic patients, in which the
safety of the PA and PAHA extracts and of three differ-
ent induction protocols were compared, demonstrated that6 Journal of Allergy
depot cluster VIT was better tolerated than PA rush VIT,
which in turn was less well tolerated than the PA cluster
protocol [18].
The eﬃcacy of the PA and PAHA preparations is sup-
ported by studies implementing sting challenges in HBV-
and YJV-allergic patients and is comparable to that of non-
puriﬁed extracts [12]. In-hospital sting challenges are the
only reliable means of evaluating the eﬀect of VIT [1]. This
procedure, however, remains an ethical issue in Italy, making
in-ﬁeld stings the only available feedback on the eﬃcacy of
the treatment. Though the observational period was over
one year and only a few patients had in-ﬁeld restings, our
experience shows that the eﬃcacy of the non-puriﬁed and
puriﬁed extracts is highly comparable.
Our study suﬀers from a few limitations which need to
be taken into account from a results point of view. Firstly, we
conducted an unblinded open trial. Despite this, the main
outcome was the incidence of SRs which should be consid-
ered as the “hard” end point. Also, the clinical definition
of SR is well deﬁned and accepted with a low margin to
subjectivity. Secondly, the sample size required to verify the
trial hypothesis was calculated in advance and the relative
risk reduction (RRR) in the number of SRs we observed
(−91%) in the puriﬁed extract-treated patients was far
greater than the RRR forecast in calculation of the sample
size (−65%).
In conclusion, our study demonstrates the superiority of
the PA extract in HBV-allergic subjects over the correspond-
ing non-puriﬁed extracts under the same rush incremental
phase.
Though similar in terms of their eﬃcacy, HB PA extracts
are safer option than NPA preparations for specialists who
perform rush VIT, followed by maintenance treatment with
the PAHA preparation. The use of the HB depot extracts for
the conventional incremental and maintenance phases could
be proposed as a workable solution for specialists with less
experience in managing VIT.
Moreover, in patients with SRs caused by both PA and
NPA extracts, the switch to a PAHA extract could be safely
made and allow the generally adequate maintenance dose of
100μgo fv e n o mt ob er e a c h e d .
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